CD37-Binding Molecules and Immunoconjugates Thereof
AssigneeImmunoGen, Inc.
InventorsJutta Deckert, Peter Park, Daniel Tavares, Lingyun Rui
Life of this patent
Estimating the term…
Abstract
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
Claims66
An antibody or antigen binding fragment thereof that specifically binds to CD37, wherein said antibody or fragment thereof is capable of inducing complement dependent cytotoxicity (CDC).
(canceled)
(canceled)
A polypeptide, antibody or antigen binding fragment thereof that specifically binds to the same CD37 epitope as an antibody selected from the group consisting of:
- (a) an antibody comprising the polypeptide of SEQ ID NO:55 and the polypeptide of SEQ ID NO:72;
- (b) an antibody comprising the polypeptide of SEQ ID NO:59 and the polypeptide of SEQ ID NO:75;
- (c) an antibody comprising the polypeptide of SEQ ID NO:61 and the polypeptide of SEQ ID NO:77;
- (d) an antibody comprising the polypeptide of SEQ ID NO:64 and the polypeptide of SEQ ID NO:80;
- (e) an antibody comprising the polypeptide of SEQ ID NO:66 and the polypeptide of SEQ ID NO:82;
- (f) an antibody comprising the polypeptide of SEQ ID NO:68 and the polypeptide of SEQ ID NO:84;
- and
- (g) an antibody comprising the polypeptide of SEQ ID NO:70 and the polypeptide of SEQ ID NO:86.
(canceled)
An antibody or antigen binding fragment thereof produced by hybridoma selected from the group consisting of ATCC Deposit Designation PTA-10664, deposited with the ATCC on Feb. 18, 2010, ATCC Deposit Designation PTA-10665, deposited with the ATCC on Feb. 18, 2010, ATCC Deposit Designation PTA-10666, deposited with the ATCC on Feb. 18, 2010, ATCC Deposit Designation PTA-10667 deposited with the ATCC on Feb. 18, 2010, ATCC Deposit Designation PTA-10668, deposited with the ATCC on Feb. 18, 2010, ATCC Deposit Designation PTA-10669, deposited with the ATCC on Feb. 18, 2010, and ATCC Deposit Designation PTA-10670, deposited with the ATCC on Feb. 18, 2010.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A human or humanized antibody or antigen binding fragment thereof that specifically binds to CD37, wherein said antibody or fragment thereof is capable of inducing apoptosis of a cell expressing CD37 in vitro in the absence of cross-linking agents.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An immunoconjugate having the formula (A)-(L)-(C), wherein:
- (A) is an antibody or antigen binding fragment that specifically binds to CD37;
- (L) is a non-cleavable linker;
- and
- (C) is a cytotoxic agent;
- and
- wherein said linker (L) links (A) to (C).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated polynucleotide comprising a sequence that encodes a polypeptide at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:
- 55-87.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.